Hi all,A quick initial look at SNT-4728. It's a tad technical to...

Hi all,

A quick initial look at SNT-4728. It's a tad technical to start but I have used the liberty of layman's terms to explain. ( I hope)

Mechanism of Action: SNT-4728 is a potent inhibitor of the enzymes SSAO (semicarbazide-sensitive amine oxidase) and MAO-B (monoamine oxidase B). These enzymes are involved in inflammatory processes and neurodegeneration, making SNT-4728 a potential neuroprotective agent by reducing neuroinflammation.

So in laymans terms to explain the previous paragraph.

Enzymes are proteins in our bodies that help speed up chemical reactions. Think of them as tiny machines that help our cells do their jobs more efficiently.

SSAO (Semicarbazide-Sensitive Amine Oxidase): This enzyme is involved in processes that can lead to inflammation and damage in tissues. It plays a role in various diseases, including those that affect the brain.

MAO-B (Monoamine Oxidase B): This enzyme breaks down certain chemicals in the brain, including dopamine, which is important for mood and movement. Overactivity of MAO-B can contribute to neurodegenerative diseases like Parkinson's.

https://syntaratx.com.au/pipeline/

SNT-4728 inhibits, or blocks, these two enzymes. By doing so, it aims to reduce inflammation and protect brain cells from damage. This could help in treating conditions like Parkinson's disease and certain sleep disorders that are linked to brain inflammation.SNT-4728 is currently in a Phase 2 clinical trial.

This trial is being conducted in collaboration with Parkinson’s UK, highlighting its potential importance in treating Parkinson's disease and related conditions.

https://www.listcorp.com/asx/snt/syntara-limited/news/first-patient-dosed-in-phase-2-trial-of-sleep-disorder-2953804.html


This is a novel compound to treat patients who are pre Parkinson's to stop development of the disease.

Is it a viable neuroprotective drug for that condition? We will await results with enthusiasm and optimism.

Parkinson's UK have provided $5.8 million for the trial, with monies repaid via a royalty stream once commercialization happens. What a grand gesture, thankyou.

Results of the trial first half 2025.

There are approximately 150 K diagnosed with that condition in Australia. Incidence increases by 4% per year. Costs Australians 10 billion $ per year in aggregate costs.

https://www.parkinsons.org.au/statistics/

Globally the figure is estimated at 9.4 million people.Is it the fastest rising by percentage disease trajectory for numbers that we as humankind are facing?

https://www.nature.com/articles/s41531-022-00284-0

Kpax. ( more SNT compounds to discuss soon)